AGEN Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -2301.55%. Agenus, Inc.'s return on equity of -- beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 195.76%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 50.25%. Given that Agenus, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Agenus, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Agenus, Inc. has a beta of 1.510, which suggesting that the stock is 51.01% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Agenus, Inc.'s net income of $63.9M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 1.05x versus 49.69x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Curis, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -243.36%. Agenus, Inc.'s return on equity of -- beat Curis, Inc.'s return on equity of -461.34%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 195.76%. On the other hand Curis, Inc. has an analysts' consensus of $16.33 which suggests that it could grow by 1206.67%. Given that Curis, Inc. has higher upside potential than Agenus, Inc., analysts believe Curis, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.510, which suggesting that the stock is 51.01% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Agenus, Inc.'s net income of $63.9M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 1.05x versus 1.19x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -30140.49%. Agenus, Inc.'s return on equity of -- beat Inovio Pharmaceuticals, Inc.'s return on equity of -252.43%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 195.76%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 277.89%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Agenus, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.510, which suggesting that the stock is 51.01% more volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.544, suggesting its more volatile than the S&P 500 by 54.377%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Agenus, Inc.'s net income of $63.9M is higher than Inovio Pharmaceuticals, Inc.'s net income of -$45.5M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 1.05x versus 448.96x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of 13.19%. Agenus, Inc.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 195.76%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 539.54%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Agenus, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.510, which suggesting that the stock is 51.01% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Agenus, Inc.'s net income of $63.9M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 1.05x versus 2.19x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.